Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
← catalyst calendarNCT07804186 · readout ≤ 2,764 d
Sponsored by IDEAYA Biosciences (industry) · IDYA — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
450estimated
Sites
1
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-04
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Sep 2026 | estimated | When the study began enrolling |
| Primary completion | Mar 2034 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2034 | estimated | The whole study's end, after follow-up |
| First posted | 2026-09-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-09-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Uveal Melanoma
Interventions
- Drug: Darovasertib
- Drug: Crizotinib (Xalkori)
Primary outcome
what the primary-completion date above is the date OFMedian relapse-free survival
measured Approximately 5 years
Related
IDYA's other studiesmost recently updated first
- A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors Phase 1 · Recruiting
- A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors Phase 1 · Active, not recruiting
- A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer Phase 1/2 · Recruiting
- A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types Phase 1 · Recruiting
- A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors Phase 1 · Recruiting
Permalink · IDYA's whole pipeline · Catalyst calendar · Every registered study · What changed